2013•Leukemia ResearchRequires access

Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia

Steven Trifilio, Zheng Zhou, Jayesh Mehta, Colleen Czerniak, Judy Pi, Deborah Greenberg, Molly Koslosky, Mihaela Pantiru, Jessica K. Altman

Open publisher page 15 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Idarubicin, Daunorubicin, Anthracycline, Medicine, Myeloid leukemia, Internal medicine, Leukemia, Pharmacology

Back to paper search Browse research topics Original source

Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia — Research Paper | ScholarLens